Royalty Report: Cancer, Drugs, Therapeutic – Collection: 230821

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 9

Primary Industries

  • Cancer
  • Drugs
  • Therapeutic
  • Medical
  • Diagnostic
  • Disease
  • HIV / AIDs
  • cell therapy
  • Pharmaceuticals
  • Device

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 230821

License Grant
Licensor, a not-for-profit pediatric health care and biomedical research services holding company,  hereby grants to Licensee an exclusive worldwide right and license in the Non-Thalidomide Field, to make, have made, use, lease, and sell the Licensed Products and to practice the Licensed Processes under the Patent Rights. Licensor shall retain a royalty-free, nonexclusive, irrevocable license to practice the Patent Rights for research purposes only.
License Property
A Licensed Product shall mean any product or part thereof which does not contain Thalidomide, alone or in combination, and which:

    *     Is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Product is made, used, or sold;

    *     Is manufactured by using a process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Process is used or in which the Licensed Product is used or sold.

A Licensed Process shall mean any process with application solely in the Non-Thalidomide Field and which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights.

Field of Use
Non-Thalidomide Field shall mean the use of any compound other than Thalidomide, alone or in combination, in humans or animals, including without limitation any and all diagnostic, prophylactic, therapeutic, and research and development uses.

Thalidomide may have use in treating diseases fed by the growth of tiny blood vessels – a growth process known as angiogenesis.

Licensee licensed the use of Thalidomide for cancer and other antiangiogenic mediated diseases from Licensor, and conducted four Phase II clinical trials and secured two orphan drug indications for the use of thalidomide in certain cancers.

IPSCIO Record ID: 203418

License Grant
Licensor grants an exclusive, worldwide right and license under the Thalidomide Patent Rights and the Mixed Patent Rights, to make, have made, use, lease, offer for sale, sell and import Products and practice Licensed Methods in the field.
License Property
The patents relate to Thalidomide.  The term Thalidomide shall mean a compound with the chemical structure described as 2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione, or as otherwise defined in the Merck Index, entry 9390, 12th ed., and pharmaceutically acceptable salts thereof.

The term product shall mean any article of manufacture, substance, material, chemical, formulation or composition for use in the Field which is or includes Thalidomide as an active ingredient, including, without limitation, a composition that comprises Thalidomide and a non-steroidal anti-inflammatory compound(s). The Product expressly excludes Thalidomide analogs.

Field of Use
The term Field shall mean the use of Thalidomide, alone or in combination, in humans or animals, including without limitation any and all diagnostic, prophylactic, therapeutic, and research and development uses.

THALOMID(R) (thalidomide), Licensee's lead product is currently marketed for the treatment of erythema nodosum leprosum, or ENL, but more widely used off-label for treating multiple myeloma and other cancers.
Erythema nodosum leprosum is one of the most frequently used terms in the science of leprosy. It is an immune-mediated complication of leprosy presenting with inflammatory skin nodules. Immune complex production and deposition as well as complement activation have long been regarded as the principal etiology of ENL. ENL is characterised by an inflammatory infiltrate of neutrophils with vasculitis. There is deposition of immune complexes and complement together with Mycobacterium leprae antigens in the skin.

IPSCIO Record ID: 286016

License Grant
Licensor of Israel hereby grants to Licensee a worldwide license to practice under the Patent Rights, and to make, have made, use, lease, and/or sell the Licensed Products in the Licensee Field and to practice the Licensed Processes in the Licensee Field, said license being perpetual unless sooner terminated as hereinafter provided and subject to the payment of royalties as hereinafter provided,  and said license to include the right to sublicense in the Licensee Field and to be exclusive to Licensee in the Licensee Field.
License Property
Patent Rights shall mean Israeli Patent Applications Nos. 83389 and 87072, filed July 30, 1987 and July 11, 1988, respectively; and any applications claiming priority or benefit directly or indirectly from either or both of them, including any continuations, continuations-in-part, and divisionals thereof; and any patents issuing from any of the foregoing, including any reissues, reexaminations, and extensions thereof; as set forth.

US Patent #5,200,553 – Biologically active carboxylic acid esters

Licensed Product(s) shall mean: Any product which is covered in whole or in part by a valid and unexpired claim contained in the Patent Rights in the country in which the product is made, used, leased, or sold; Any product which is manufactured by using a process which is covered in whole or in part by a valid and unexpired claim contained in the Patent Rights in the country in which the process is used; Any product which is used according to a method which is covered in whole or in part by a valid and unexpired claim contained in the Patent Rights in the country in which the method is used.

Licensed Process(es) shall mean any process or method, which is covered, in whole or in part, by a valid and unexpired claim contained in the Patent Rights in the country in which the process or method is used.

Field of Use
Licensee Field shall mean: (a) with respect to butylidene dibutyrate (sometimes referred to as AN-10), non-topical applications for oncologic disorders; and (b) with respect to all other products within the Patent Rights, all indications and routes of administration except (i) the treatment of (-hemoglobinopathies ((-globin disorders) and (ii) topical applications other than oncologic disorders. The term oncologic disorders shall not include chemotherapy-or radiotherapy-induced alopecia.

IPSCIO Record ID: 203485

License Grant
The University grants the worldwide right and license to make, have made, use, lease and sell the Licensed Products, and to practice the Licensed Processes.

Licensor agrees that it shall not grant any other license to make, have made, use, lease and sell Licensed Products or to utilize Licensed Processes in the Research or In Vitro Diagnostics fields and in the In Vivo Diagnostics field and the Therapeutics field of use during the period.

At the end of the exclusivity period, the Licensee may extend the exclusivity or the rights will change to non-exclusive for the remainder of the term of the agreement.

Licensor agrees that its grant to Licensee to use of the Tangible Property for commercial purposes shall be exclusive in perpetuity unless this Agreement is terminated prior to the last to expire of the Patent Rights.

License Property
Licensor is the owner of certain Patent Rights relating to Method For Determining Tissue Of Origin And Degree Of Malignancy Of Tumor Cells.  The patent applications as of this agreement, include but are not limited to, A method for determining the tissue of origin of a cell and degree of malignancy, and, The method wherein tho nuclear matrix proteins are isolated, and, The method wherein the cytoskeleton proteins are solubilized, and, A method for detecting tumor antigens in a body fluid comprising reacting labeled monoclonal antibodies to nuclear matrix proteins of known origin and degree of malignancy with the body fluid to be analyzed .

The Tangible Property shall mean any or all of the hybridorna cell lines from the Licensors laboratory with the designation(s) MCF-7 Bl through B9.

A Licensed Product shall mean any product or part thereof which:
(a)  is covered in whole or in part by a pending claim contained in a Patent Rights Patent Application in the country in which any Licensed Product is made, used or sold; or, a valid and unexpired claim contained in a Patent Rights Patent in the country in which any Licensed Product is made, used or sold; or
(b)  is manufactured using a process which is covered in whole or in part by a pending claim contained in a Patent Rights Patent Application in the country in which any Licensed Process is used, or, a valid or unexpired claim contained in a Patent Rights Patent in the country in which any Licensed Process is used; or,
(c)  is developed or manufactured using the Tangible Property.

A Licensed Process shall mean any process for making Licensed Products which is covered in whole or in part by:
(a)  a pending claim contained in a Patent Rights Patent Application; or
(b)  a valid and unexpired claim contained in a Patent Rights Patent; or which
(c)  uses the Tangible Property.

Field of Use
The fields of use are Research or In Vitro Diagnostics fields and in the In Vivo Diagnostics field and the Therapeutics field.

The Licensee develops, produces and distributes products for the diagnosis and potential treatment of cancer based on its proprietary nuclear matrix protein technology.

IPSCIO Record ID: 230759

License Grant
The University grants the non-exclusive right and license to make, have made, use, lease and sell the Licensed Products, and to practice the Licensed Processes in the Territory for the Fields of Use to the end of the term for which the Patent Rights are granted unless sooner terminated according to the terms hereof.
License Property
The patent is for AAV Transduction Vectors.

A Licensed Process is any process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights; or, Patent Rights; or, is derived from Patent Rights or know-how, and related to or described in is sold, manufactured or used in any country under this Agreement.

A Licensed Product shall mean any product or part thereof which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Products are made, used or sold; or,  is manufactured by using a process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Process is used or in which such product or part thereof is used or sold; or,
is derived from Patent Rights or know-how, and related to or described in Patent Rights.

Field of Use
The Fields of Use shall mean:
(a) Human [blood] disorders, [metabolic and congenital]. This field includes human [hematological] diseases that arise due to the absence, over-expression or altered expression of proteins normally (present in blood]. The primary site and location of these proteins is [blood]. Specifically included are human [hemoglobinopathies (i. e. Sickle Cell Anemia and Thalassemia)] and human disorders of the [coagulation metabolism (i.e., Hemophilia A (factor VIII), Von Willebrands Disease (factor VIII) and Hemophilia B (factor IX))]. Specifically excluded are human [neoplasias of the lymphoreticular system (lymphomas, reticuloendothelioses, or plasma cell dyscrasias)].

(b) Human [malignant neoplastic] diseases. This field includes all forms of human (cancer, including but not limited to skin cancers and all solid tumors]. This field also includes all forms of human [cancers of the hematopoietic tissues (the leukemias), Hodgkins Disease and Non-Hodgkins Lymphoma].

c) relating to a syndrome (AIDS) characterized by opportunistic infections occuring as a result of profound
deficiency of the helper – T4 lymphocytes (CD4 lymphocytes). At any time during the life of this Agreement the definition of AIDs shall be that definition currently in use by the Centers for Disease Control, Atlanta, Georgia].

(d) All human [infectious diseases other than HIV]. This Field includes: [human viral diseases (besides HIVs, human bacterial, yeast and other microorganism based diseases, and all other human infectious diseases.

IPSCIO Record ID: 233463

License Grant
Licensor, non-profit organization, grants the exclusive worldwide right and license to make, have made, use, lease and sell the Licensed Products, and to practice the Licensed Processes to the end of the term for which the Patent Rights are granted unless sooner terminated according to the terms.
License Property
The patent is for Endostatin, An Inhibitor of Angiogenesis, and the Licensed Product or Licensed Process shall mean any process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights.

Angiogenesis is the biological process by which new blood vessels are formed and primarily occurs during the first three months of embryonic development.

Field of Use
Licensee is capable of the development. production, manufacture, marketing and sale of products similar to the Licensed Products and/or the use of the Licensed Processes and that it shall commit itself to a thorough, vigorous and diligent program of exploiting the Patent Rights so that public utilization shall result therefrom.

The Licensee is currently developing two endogenous proteins, Angiostatin(TM) and Endostatin(TM), as potential long term cancer therapeutics to prevent metastatic disease and as therapies for primary tumors. These two proteins are different in structure and origin but have similar activity.

IPSCIO Record ID: 26020

License Grant
Licensor hereby grants to Licensee a world-wide, exclusive royalty-bearing license, with the right to sublicense under Licensors entire right, title and interest in and to the Analog Patents, to make, use, offer for sale, sell, import, practice, and otherwise dispose of any and all Licensed Products and Licensed Methods in the Analog Field.
License Property
Licensed Product means and includes (a) any Amino Thalidomide Product; (b) any Revimid Product; (c) any product, the making, using, offering for sale, sale, or importation of which, by an unlicensed third party, would infringe any of the Analog Patents; and (d) any product that is disclosed as a species or encompassed by a genus described at column 7, line 1 through column 11, line 50 of U.S. Patent No. 5,712,291 which will not be unreasonably interpreted to encompass products that are not genuine thalidomide analogues including, without limitation, compounds currently referred to as SelCids(TM).

Thalidomide means the chemical described as 2-(2,6- Dioxo-3-piperidinyl)-lH- isoindole-1,3(2H)-dione

Thalidomide Analog means and includes any and all analogs, metabolites, precursors, and hydrolysis products of Thalidomide, and all stereoisomers of each of the foregoing, including without limitation (a) all such compounds disclosed, generically or specifically, or claimed by any of the Analog Patents, (b) Amino Thalidomide and all stereoisomers and metabolites thereof; and (c) Revimid, and all stereoisomers and metabolites thereof.

Thalidomide is used along with dexamethasone to treat multiple myeloma in people who have been recently found to have this disease. It is also used alone or with other medications to treat and prevent skin symptoms of erythema nodosum leprosum (ENL; episodes of skin sores, fever, and nerve damage that occur in people with Hansen's disease [leprosy]). Thalidomide is in a class of medications called immunomodulatory agents. It treats multiple myeloma by strengthening the immune system to fight cancer cells. It treats ENL by blocking the action of certain natural substances that cause swelling.

Field of Use
Analog Field means and includes any and all uses of any Thalidomide Analog, alone or in combination, including without limitation (a) in humans and animals, and (b) for any and all diagnostic, prophylactic, therapeutic, and research and development uses.

IPSCIO Record ID: 227272

License Grant
Licensor Institute, a nonprofit American medical research facility, grants an exclusive, worldwide license, including the right to sublicense, to Licensors Technology and under Licensors Patent Rights, to make, to have made, to import, to use, to offer for sale, and to sell Licensed Products in the Field.

This agreement also contains a non-exclusive grant back from Licensee to Licensor.

License Property
The patents are for Methods and Compositions for Enhancing Angiogenesis, Methods and Compositions for Modulation T-cell Activation and Uses thereof, and, Methods for Detecting Vasculopathies and Tumors.

Technology relates to angiogenesis, including anti-angiogenic diagnostic applications.
Angiogenesis means the growth of new blood vessels. Anti angiogenic drugs are treatments that stop tumours from growing their own blood vessels. If the drug is able to stop a cancer from growing blood vessels, it might slow the growth of the cancer or sometimes shrink it.

Field of Use
The term Field shall mean human therapeutic and diagnostic applications and shall specifically exclude any Agricultural Product.

Licensee is engaged in research and development of biotechnology and pharmaceutical products which regulate the growth of new blood vessels.

IPSCIO Record ID: 289227

License Grant
University hereby grants Licensee the exclusive right to conduct various technical, pre-clinical, marketing, patent, and other studies on Products in the field of use during a six (6) month period commencing on the effective date of this Agreement (the option period). The option period may be extended by mutual written agreement of the parties.

In consideration of the royalties, and subject to the terms and conditions, as set forth in this Agreement and effective upon the earlier to occur of (i) written notification to University during the option period that Licensee desires to license the Patent(s), or (ii) expiration of the option period with no written notification given, University hereby grants to Licensee: i. the exclusive worldwide license in the field of use to use the Patent to make, have made, use distribute, and sell the Product(s); and ii. the right to grant sublicenses to any Patent licensed hereunder, provided that any sublicensee agrees to be bound by the terms and conditions of this Agreement applicable to sublicensees.

License Property
The term Patent or Patents shall mean any and all patent applications listed while, and to the extent, said applications remain pending, and any and all pending or unexpired patents issued thereon and any continuation, division, extension or reissue thereof, and any and all pending or unexpired foreign patents issuing from any application filed which corresponds to claims contained in any of the foregoing patents or applications.
USC#2860, filing date 12/15/1999

Product or Products shall mean any article, composition, apparatus, substance, chemical, material, method or service which is made, used, distributed or sold by Licensee which:
i. is covered in whole or in part by one or more pending or unexpired claims contained in a Patent in the country in which the Product(s) is made, used, distributed or sold;
ii. is manufactured using a method or process which is covered in whole or in part by one or more pending or unexpired claims contained in a Patent in the country in which (a) the Product(s) is made, use, distributed or sold, or (b) the method or process is used or sold;
iii. the use of which is covered in whole or in part by one or more pending or unexpired claims contained in a Patent in the country in which (a) the Product(s) is made, used, distributed or sold, or (b) the method or process is used or sold; or
iv. incorporates Information transferred to Licensee pursuant to the confidential disclosure agreement dated January 7, 2000 between University and Licensee (as the term Information is defined in said agreement).

Field of Use
Field of Use shall mean (i) human and veterinary diagnostic laboratory services or (ii) the sale of clinical diagnostic products, and (iii) the sale of research products to the research community.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.